|Bid||110.25 x 1300|
|Ask||110.29 x 800|
|Day's Range||109.77 - 111.05|
|52 Week Range||89.01 - 122.97|
|PE Ratio (TTM)||10.24|
|Beta (3Y Monthly)||1.44|
|Expense Ratio (net)||0.47%|
Novocure Ltd. said Thursday Chief Science Officer Eilon Kirson will retire after about 7 years in the role, and 17 years with the company. The cancer treatment company said Kirson's retirement provides the opportunity to separate medical and scientific responsibilities. Uri Weinberg, vice president of clinical development, will assume responsibilities for preclinical and clinical development and regulatory affairs effective immediately, and Ely Benaim will join the company as chief medical officer effective April 1, assuming responsibilities for clinical operations, medical affairs and safety. The stock, which is still inactive in premarket trade has soared 67.8% over the past three months, while the iShares Nasdaq Biotechnology ETF has rallied 24.6% and the S&P 500 has climbed 16.9%.
Shares of Aerpio Pharmaceuticals Inc. plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopathy failed to meet its primary endpoint of improvement over placebo. The stock was the biggest decliner listed on major U.S. exchanges, with volume reaching 5.5 million shares, or about 22 times the full-day average. Meanwhile, the company said the trial of its lead candidate AKB-9778 was found did to be safe and well tolerated and showed some encouraging in some secondary endpoints. "While we are disappointed in the primary endpoint results of this study, we are nevertheless encouraged by the fact that several other promising findings observed in our prior 3-month Phase 2a trial have been prospectively confirmed in this 1-year trial," said Chief Executive Stephen Hoffman. The company said it plans to provide an update on the status of AKB-9778 after a full analysis. The stock has now lost 37% over the past 3 months while the iShares Nasdaq Biotechology ETF has gained 16% and the S&P 500 has tacked on 11%.
Shares of Daré Bioscience Inc. rocketed 129% on very heavy volume toward a 13-month high in afternoon trade Monday, after the biopharmaceutical company announced positive findings for the use of its DARE-VVA1 product candidate in treating vulvar and vaginal atrophy (VVA). The stock was the biggest percentage gainer listed on major U.S. exchanges, even though it pared earlier gains of as much as 253%. Volume swelled to 37.8 million shares, compared with the full-day average of about 82,500 shares and enough to make the stock the most active on the Nasdaq exchange. The company said a self-administered vaginal suppository containing tamoxifen administered to four healthy postmenopausal women with VVA showed "significant improvements" in reducing vaginal pH and vaginal dryness, without significant absorption of tamoxifen. "If successful, DARE-VVA1 could be the first and only vaginally administered tamoxifen product approved by the FDA for the treatment of VVA in hormone-receptor positive breast cancer patients," the company said in a statement. The stock has now more than tripled year to date (up 218%), while the iShares Nasdaq Biotechnology ETF has climbed 18% and the S&P 500 has gained 13%.
Shares of PhaseBio Pharmaceuticals Inc. more than doubled in premarket trade Monday, soaring 112% toward a record high, after the biopharmaceutical company announced positive phase 1 trial results of PB2452, a reversal agent for the antiplatelet drug ticagrelor. The trial showed that the effects of PB2452 were immediate, with sustained reversal of ticagrelor antiplatelet effects without reports of drug-related serious adverse events. "The data support further evaluation of PB2452 for the reversal of the antiplatelet effects of ticagrelor in emergency situations involving major bleeding and to enable emergent or urgent surgery in patients," said Deepak Bhatt, executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital. The company is planning to initiate a phase 2a trial in the first half of this year. The stock, which went public in October, has lost 9.5% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has run up 16% and the S&P 500 has gained 11%.
Shares of Akari Therapeutics PLC more than doubled--soaring 145%--toward a 15-month high in very active morning trade Wednesday, enough to pace all the gainers on the Nasdaq exchange, after the company said it plans to commence trials in European and U.S. pediatric patients this year for its treatment of pediatric thrombotic microangiopathy. Trading volume rocketed to 22.3 million shares, compared with the full-day average of about 20,000 shares. The company said it had a "successful," pre-investigational new drug (IND) meeting with the Food and Drug Administration regarding its pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), which is an orphan condition with an estimated fatality rate of 80%. Chief Executive Clive Richardson said trials in HSCT-TMA patients are planned to begin in the fourth quarter. "We see HSCT-TMA as a gateway indication into a range of other poorly treated orphan TMAs, and are enthusiastic about the potential of Coversin to offer an improved standard of care for patients with these rare and usually fatal conditions," Richardson said. The stock has now run up 93% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has slipped 1.1% and the S&P 500 gained 0.9%.
Last week was an event-filled one for the biotech space, with M&A, FDA decisions, clinical trial results and earnings all on offer. Biogen Inc (NASDAQ: BIIB ) announced an $800-million deal to buy Nightstar ...
Biotech stocks turned lower after news reports on Tuesday afternoon that Food and Drug Administration Commissioner Scott Gottlieb was resigning. The iShares Nasdaq Biotechnology ETF was down 0.3% after being up 0.5% just before the news. The ProShares Ultra Nasdaq Biotechnology ETF fell 0.6%, while the SPDR S&P Biotech ETF fell 0.2% . Biotech and pharmaceutical executives have praised Gottlieb for accelerating the approval of generic drugs and updating the process for FDA evaluation of novel treatments such as gene therapy.
Shares of Nightstar Therapeutics PLC rocketed 67% to pace all premarket gainers in very active trade, after the gene therapy company agreed to be acquired by Biogen Inc. in a cash deal valued at about $877 million. Trading volume in Nightstar spiked to over 570,000 shares, compared with the full-day average of about 71,300 shares. Under terms of the deal, U.K.-based Nightstar shareholders will receive $25.50 for each Nightstar share they own, which represents a 68% premium to Friday's closing price of $15.16. The deal is expected to become effective by mid-year 2019. "This transaction accelerates treatment to patients through Nightstar's key retinal gene therapy programs that modify or halt progression of blindness," said Nightstar Chief Executive David Fellows. Nightstar shares have climbed 15.7% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has gained 5.0% and the S&P 500 has advanced 4.2%.
Shares of Immunogen Inc. plummeted 48% toward a two-year low in premarket trade Friday, after the company said a phase 3 trial of its ovarian cancer treatment, mirvetuximab soravtansine, compared to chemotherapy, failed to meet its primary endpoint of progression free survival. The company said that based on the efficacy signals, overall response rate and survival, it will conduct additional analysis to evaluation the potential benefit of mirvetuximab soravtansine for FRα-positive platinum-resistant ovarian cancer. "ImmunoGen is in a strong financial position with approximately $295 million in cash on our balance sheet, and we will continue to advance our portfolio of next-generation ADCs, which includes three additional development candidates targeting a range of tumor types in both hematologic malignancies and solid tumors," said Chief Executive Mark Enyedy. The stock has tumbled 57% over the past 12 months through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 5.3% and the S&P 500 has tacked on 4.0%.
After slumping last year, biotechnology stocks and the related exchange traded funds (ETFs) are on the mend in 2019. Last year, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), the largest biotech ETF by assets, slipped 9.5%.With almost two months of 2019 in the books, IBB has recouped all of those losses and then some as the benchmark biotechnology ETF is higher by nearly 17% this year. Amid ongoing industry consolidation, attractive valuations for a group that is often richly valued and a strong broad market, catalysts are in place for more upside for biotechnology ETFs.Jefferies analyst Michael Yee "writes that third-party data shows that the fourth quarter saw not only the biggest actively managed fund outflows in the biopharma space in 15 years, but outflows that were double the biotech bear market of 2016," according to Barron's.InvestorPlace - Stock Market News, Stock Advice & Trading TipsStill, flows data suggest investors need some convincing about returning to biotechnology ETFs. Year-to-date, IBB has lost $382.28 million in assets. * 7 IPOs to Get Excited for in 2019 Those outflows should convince investors to shy away from biotechnology ETFs. Here are some fine ideas among biotech ETFs to consider right here, right now. ALPS Medical Breakthroughs ETF (SBIO)Expense Ratio: 0.5% per year, or $50 on a $10,000 investment.For investors willing to take some more risk due to the fund's mid- and small-cap composition, the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) is one of the best alternatives to traditional biotech ETFs. SBIO member firms have market values ranging from $200 million to $5 billion.That puts the fund at the epicenter of some prominent biotech themes. SBIO is not designed to be a takeover fund, but with market caps that do not exceed $5 billion when the fund rebalances, SBIO components have frequently been mentioned as takeover targets or outright acquired in the fund's four-plus years on the market.Second, smaller biotech companies are often more sensitive to positive trial news than large-cap counterparts, which is relevant to SBIO because the fund only holds companies with drugs or treatments in Phase II of Phase III clinical trials. Invesco Dynamic Biotechnology & Genome ETF (PBE)Expense Ratio: 0.59%The Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) is a biotech ETF to consider for investors looking for a unique weighting methodology. This $281.4 million fund follows the Dynamic Biotech & Genome Intellidex Index."The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value," according to Invesco. * 10 Blue-Chip Stocks to Lead the Market Over the past three years, this biotech ETF has handily outperformed IBB, and much of that out-performance is attributable to the size factor. Currently, over 70% of PBE's 29 holdings are classified as mid- or small-cap stocks. Invesco S&P SmallCap Health Care ETF (PSCH)Expense Ratio: 0.29%Small-cap ETFs can offer big returns, and for investors willing to get tactical, some sector funds in this space can really pack a punch. That group certainly includes the Invesco S&P SmallCap Health Care ETF(NASDAQ:PSCH).As its name implies, PSCH is a broader healthcare fund, not a dedicated biotech ETF, but the combination of healthcare and small-cap stocks often means significant biotechnology exposure. PSCH obliges with a 19.46% to biotechnology stocks. Not surprisingly, PSCH is predominantly a small-cap growth fund as about 72% of its 69 holdings are classified as small-cap growth stocks.Since inception nearly nine years ago, PSCH has beaten the S&P SmallCap 600 Index by more than 700 basis points. Global X Longevity Thematic ETF (LNGR)Expense Ratio: 0.5%The Global X Longevity Thematic ETF (NASDAQ:LNGR) is a thematic fund focusing on the issue of rapidly aging populations in some of the world's largest economies. Via that focus, LNGR has some credibility as a biotechnology ETF as biotech stocks represent around a third of the fund's weight.While LNGR is a highly focused fund and still small in terms of assets, there are compelling long-term trends backing its investment thesis. * 7 Cheap Stocks That Make the Grade "As more people age, there will simply be greater demand for treatments, both old and new, to prevent, mitigate and ideally cure such diseases," according to Global X research. "Innovations in technology and biotech research, including the use of genomic data and bioinformatics for personalized care, can offer further solutions in this space." ARK Genomic Revolution ETF (ARKG)Expense Ratio: 0.75%The actively managed ARK Genomic Revolution ETF (NYSEARCA:ARKG) is not a biotechnology ETF, but it focuses on some of the most compelling healthcare opportunities, including bioinformatics, CRISPR, molecular diagnostics, stem cell therapies and more."Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business," according to ARK Investment Management.The $254 million ARKG usually holds 30 to 50 stocks and the current weighted average market value of its holdings is $30 billion. While ARKG is pricier than traditional healthcare and biotech ETFs, the fund is worth the higher fee. Over the past three years, ARKG is up 91.3%, nearly doubling the returns of the S&P 500 Health Care Index. First Trust NYSE Arca Biotechnology Index Fund (FBT)ExpenseRatio: 0.56%The First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) is one of the largest and more traditional biotech ETFs. Home to 30 stocks, FBT follows the NYSE Arca Biotechnology Index.Although FBT appears to be a basic big pharma ETF, none of its holdings exceed weights of 3.94% and the size factor is at play with this fund as highlighted by a median market capitalization of $8.18 billion for its holdings. * 9 High-Growth Stocks to Buy Now for Monster Returns Tilting toward small biotech stocks has helped FBT top the largest cap-weighted biotech ETF by a margin of better than 2-to-1 over the past 36 months. During that span, FBT has only been slightly more volatile than its cap-weighted rival. Principal Healthcare Innovators Index ETF (BTEC)Expense Ratio: 0.42%The Principal Healthcare Innovators Index ETF (NASDAQ:BTEC), which debuted in August 2016, is another example of a thematic approach to healthcare investing. BTEC tracks the Nasdaq U.S. Healthcare Innovators Index, which is comprised of early stage, small-cap names."These are primarily biotechnology and life science, which have the potential to create cures for cancer, develop new medical technologies, or spearhead other medical advances," according to ETF Trends.BTEC is not a pure biotech ETF, but at the end of last year, 60.57% of the fund's weight was allocated to biotech stocks. When BTEC rebalances none of its holdings exceed weights of 3% and at the end of 2018, the fund's top 10 holdings represented just over 29% of its weight. Those are two traits that help diminish concentration risk.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post 7 of the Best Biotech ETFs appeared first on InvestorPlace.
Shares of Anchiano Therapeutics Ltd. was on track to close below its initial public offering price on its debut, bucking the gains in its Nasdaq biotechnology peers and the broader stock market. The stock's first trade was at its IPO price of $11.50 at 10:02 a.m. Eastern, and that was the highest price it traded. The Israel-based biotechnology company's stock fell as much as 8.3% below its IPO price, at the intraday low of $10.55, but has pared some losses to be down 6.4% in recent trade. Meanwhile, the iShares Nasdaq Biotechnology ETF was up 0.9% in afternoon trade while the S&P 500 was rallying 1.3%.
Israel-based Anchiano Therapeutics Ltd. said Tuesday said the initial public offering of American Depositary Shares had priced at $11.50 each. With the biotechnology company is offering 2,652,174 ADS to raise $30.5 million, and could raise up to $35.1 million if options granted to underwriters are exercised. The company had previously said it assumed an initial public offering price of $14.55 per ADS. The stock is expected to begin trading Tuesday on the Nasdaq Capital Market under the ticker symbol "ANCN." The company's lead underwriters are Oppenheimer and Ladenburg Thalmann. The company is going public at a time that iShares Nasdaq Biotechnology ETF has gained 3.7% over the past three months through Monday and the Renaissance IPO ETF has rallied 7.8%, while the S&P 500 has slipped 0.6%.
Shares of newly public biopharmaceutical company Alector Inc. opened just shy of its initial public offering price, before swinging slightly higher in morning trade. The first trade was at $18.70 for about 542,000 shares at 10:39 Eastern, which was 1.6% below the $19 IPO price. The stock was last trading 0.5% above its IPO price. The stock is listed on Nasdaq under the ticker symbol "ALEC." The company has gone public at a time when the iShares Nasdaq Biotechnology ETF has lost 2.1% over the past three months, while the Renaissance IPO ETF has gained 1.2% and the S&P 500 has declined 3.6%.
The bullish news triggered a minor uptick that reversed at range resistance in place since an October 2018 breakdown, but thin pre-market volume may not reflect buying and selling power after the opening bell. Biotech stocks have struggled since 2015 when Valeant Pharmaceuticals and Turing Pharmaceuticals provoked nationwide outrage and price gouging charges that eventually lead to Martin Shkreli's imprisonment and Valeant's rebranding as Bausch Health Companies Inc. (BHC).
Is AbbVie an Attractive Buy after Q4 2018 Results?Share price movements On January 25, AbbVie (ABBV) closed at $80.54, which is 6.22% lower than its previous closing price. The steep drop came as a reaction to the company’s Q4 2018 and fiscal 2018
Shares of Amgen Inc. were down 1.4% in premarket trade Monday after the company was downgraded to in-line from outperform by Evercore ISI, with analyst Umer Raffat citing patent concerns. Amgen stock's strong performance since 2011 has largely been due to a delay in biosimilar competition, Raffat said in a note to investors, but that is no longer the case. A court decision on Amgen's biggest drug, Enbrel, is imminent, and a biosimilar by Novartis's Sandoz already has tentative approval, Raffat said. Shares of Amgen have gained 2.1% in the year to date through Friday, while the iShares Nasdaq Biotechnology ETF has gained 13.5%. The S&P 500 has gained 6.3%.
Shares of MacroGenics, Inc. gained 4% on Friday after the company announced that the U.S. Food and Drug Administration had lifted a partial clinical hold on its Phase 1 studies of a potential monoclonal antibody-based cancer treatment, allowing researchers to continue enrolling new patients in the U.S. In December, MacroGenics announced that the FDA had placed the studies on partial clinical hold after the company reported kidney-related adverse events in some subjects. During the hold, researchers were not allowed to enroll new patients, but previously-enrolled participants were allowed to continue receiving the drug. Shares of MacroGenics have fallen 6.5% in the year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 13%. The S&P 500 has gained 6.4%.
In 2018, instead of getting a Santa Claus rally we got a December rout. Stocks cratered into Christmas, and Intuitive Surgical (NASDAQ:ISRG) fell 20% in as many days. Luckily, its investors know the value of the company so it made a complete recovery in about the same amount of time. The dip was not specific to ISRG since the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) stock had a similar path for the same period of time. After the sharp recovery, Intuitive Surgical came into last night's earnings report perfectly set up for a dip. The stock had a lot of momentum -- perhaps too much. Regardless of the quality of the report, it was almost destined to fall on the news simply from the technical aspect. First the impressive "V" recovery usually needs back-and-fill sessions before bulls can continue higher. Furthermore, ISRG stock had reached a level which had been prior failures five times before within the last 12 months. There is no shame in falling in order to reload another leg higher. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Last night management reported earnings, and investors hated what they saw. The stock fell 5% on the headline. I bet that fans of the stock will not be shy about buying the dip. It will be a matter of time. If the stock markets are higher then so will Intuitive Surgical stock. ### Where ISRG Stock Stands This is a stock I'd own for the long term. There might be short-term pain, but the trajectory is clear up and to the right. Dips in ISRG are opportunities to add or start a position in it. * 5 of the Best Stocks to Buy and Hold for the Long Term So management missed on earnings expectations, but delivered double-digit growth on almost everything else. This does not make for a bad quarter. If anything it was probably a bad forecast. Even then, missing earnings is usually an easy fix. They can find the culprit line item and fix it going forward. This is not the same as saying that there is a structural problem with the company that will linger going forward. From a price action perspective, there is benefit from having a recent sharp correction. It gives us a floor against which we can gauge new risk. In this case, a 5% after-hours dip brings it close to support levels. From a trading perspective, $515 per share area is the point of interest for the last two months. This means that both bulls and bears agree on it, so they will fight it out. This creates congestion which on the way down translates into support. Even if that fails, there are more support levels below, all the way down to $480 per share. Long-term holders of the stock should be comfortable inside those ranges. Intuitive surgical stock will need the help of the market in general. The macroeconomic environment is still in headline mode. We have political rhetoric and tariff headlines littering the ticker tapes. So it is entirely possible that we will revisit the February lows one more time if politicians continue their verbal combat. But even if we do, that will also be a buying opportunity -- and a better one than this recovery that is ongoing in 2019. Companies are still making a lot of money and their balance sheets are healthy. This is not 2008 and we do not have bubbles. Yes, we are close to all-time highs, but we did that on good solid fundamentals. So far companies are reporting strong results and the mega-caps will continue their headlines next week. Except for a few questionable ones, most are likely to deliver good news. So dips will be bought, and that means that ISRG stock will find it easier to shrug any short term negativity. Fundamentally speaking, this company has value. It sells at trailing-12-months price-earnings ratio of 51, according to Zacks. While this sounds high, it is not bloated for a company that delivers growth. For perspective, it is more expensive than Alphabet's (NASDAQ:GOOG, NASDAQ:GOOGL) 25 P/E, but cheaper than, say, Chipotle (NYSE:CMG) at 63X. So although not cheap, there is not a lot of froth to shed. Even though Wall Street's knee-jerk reaction last night meant that they did not approve of the report, management still delivered double-digit growth on almost all metrics. So they have a solid base on which to continue building future ISRG business. There aren't a lot of competitors in the field, and this one has established a strong foothold, making it difficult to circumvent. I bet that they will be able to continue to successfully execute on plans for years to come. This is a stock to own now but since we have so many threats still in the news and deadlines looming through March, it's probably best to build a position in tranches. This way I would have room to add to it in case there is another leg lower. A 5% fall after hours it's not a deal-breaker for a stock like Intuitive Surgical. The analysts on Wall Street agree as most of them have it as a stock to "buy," and it is still trading below their average price target. I doubt that this report they delivered last night is ugly enough for them to change their ratings. Click here for a bonus video on how to create income from nothing using FedEx(NYSE:FDX) stock as an example. Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Semiconductor Stocks to Buy Now * 10 of the Best Stocks to Invest In for February * 5 Top Stocks for a FOMO Rally Compare Brokers The post Intuitive Surgical Stock Dips Are Buying Opportunities appeared first on InvestorPlace.